ArticleJournal of cellular and molecular medicine2025
FKBP5 Regulates Osteogenesis of Human iPSC-Derived Mesenchymal Stem Cells via FKBP5-AKT-FOXO1 Pathway.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Time-course ATAC-seq and RNA-seq analysis of porcine synovium-derived mesenchymal stem cells under in vitro osteogenic induction.Epigenetics & chromatin · 2026Article
- FKBP5 Regulates Osteogenesis of Human iPSC-Derived Mesenchymal Stem Cells via FKBP5-AKT-FOXO1 Pathway.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The induced pluripotent stem cells derived mesenchymal stem cells (iMSCs) have shown great promise for bone tissue regeneration in critical-sized calvarial defects. Still, the roles of FKBP5 in its osteogenesis are rarely known. It was observed that FKBP5 increased rapidly in iMSCs following osteogenic differentiation. To elucidate its role, FKBP5 was knocked down or overexpressed by lentivirus infection. Interestingly, the down-regulation of FKBP5 impaired the osteogenesis of iMSCs, whereas the up-regulation of FKBP5 promoted it. Proteomics analysis of iMSCs/oeFKBP5 and iMSCs/oeNC revealed that the protein variances are enriched in several signalling pathways associated with osteogenesis. Notably, the PI3K-AKT signalling pathway was enriched highly at both D4 and D14. Co-immunoprecipitation results demonstrated that the binding proteins of FKBP5 are AKT and pS473-AKT, but not PI3K/p-PI3K or FOXO1/pS256-FOXO1; however, the ratios of pS473-AKT/AKT and pS256-FOXO1/FOXO1 were down-regulated by FKBP5. FOXO1 inhibitor AS1842367 lessened the enhanced osteogenesis by FKBP5. Moreover, in a rat critical-sized calvarial defect model, the iMSCs/oeFKBP5 delivery exhibited improved bone regeneration capability than iMSCs/oeNC in vivo. In conclusion, our findings first revealed that FKBP5 promotes the osteogenic differentiation of iMSCs partially through the FKBP5-AKT-FOXO1 pathway and presents a promising approach to iMSCs transplantation for clinical bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.